Management of acute coronary syndromes. Variations in practice and outcome: Findings from the Global Registry of Acute Coronary Events (GRACE)

European Heart Journal

Volumn 23, Issue 15, 2002, Pages 1177-1189

  Fox, Keith A A ^a   Goodman, S G ^b   Klein, W ^c   Brieger, D ^d   Steg, G ^e   Dabbous, O ^f   Avezum, A ^g  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Klinische Abteilung für Kardidogie   (Austria)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e BICHAT HOSPITAL   (France)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Acute coronary syndromes; GRACE; Myocardial infarction; Observational studies; Registry; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARGENTINA; ARTICLE; AUSTRALIA AND NEW ZEALAND; BRAZIL; CANADA; DEMOGRAPHY; ELECTROCARDIOGRAM; EUROPE; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY CONTROL; REGISTER; ST SEGMENT ELEVATION; THORAX PAIN; UNITED STATES; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; AUSTRALIA; CANADA; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEW ZEALAND; NORTH AMERICA; REGISTRIES; SOUTH AMERICA; TREATMENT OUTCOME;

EID: 0036700407     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3081     Document Type: Article

References (28)

1. The GRACE Investigators. GRACE (Global Registry of Acute Coronary Events): A multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001; 141: 190-9.
2. Fox KAA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G. The ENACT study: A pan-European survey of acute coronary syndromes. Eur Heart J 2000; 21: 1440-9.
3. Topol EJ. Targeted approaches to thrombosis inhibition - An end to the shotgun approach. Clin Cardiol 1997; 20 (Suppl I): 122-126.
4. American Heart Association. 2000 Heart and Stoke Statistical Update. Dallas, Texas. American Heart Association, 1999.
5. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P, for the WHO MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-Year results from 37 WHO MONICA Project populations. Lancet 1999; 353: 154-7.
6. Akkerhuis KM, Deckers JW, Boersma E et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J 2000; 21: 371-81.
7. Kong DF, Blazing MA, O'Connor CM. Advances in the approach to Acute Coronary Syndromes. Hosp Pract 2000; 35: 61-74.
8. Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction). J Am Coll Cardiol 1999; 34: 890-911.
9. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with unstable angina). Circulation 2000; 102: 1193-1209.
10. Collinson J, Flather MD, Fox KAA et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective registry of acute ischemic syndromes in the UK (PRAIS-UK). Eur Heart J 2000; 21: 1450-7.
11. Theroux P, Fuster V. Acute coronary syndromes. Circulation 1998; 97: 1195-1206.
12. Fox KAA, Goodman S, Bigonzi F, Le Louer V, Cohen M and The ESSENCE Trial Investigators. Inter-regional differences and outcome in unstable angina. Eur Heart J 2000; 21: 1433-9.
13. Maynard SJ, Scott GO, Riddell JW, Adgey AAJ. Management of acute coronary syndromes. BMJ 2000; 321: 220-3.
14. Alpert JS. Are data from clinical registries of any value? Eur Heart J 2000; 21: 1399-1401.
15. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569- 82.
16. Yusuf S, Flather M, Pogue J et al. for the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry Investigators. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998; 352: 507-14.
17. O'Shea JC, Califf RM. Inter-regional differences in acute coronary syndrome trials. Eur Heart J 2000; 21: 1397-9.
18. Akkerhuis KM, Deckers JW, Boersma E et al. for the PURSUIT Investigators. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Eur Heart J 2000; 21: 371-81.
19. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
20. Kereiakes DJ, Grines C, Fry E et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13: 272-8.
21. Ferguson JJ. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. National Investigators Collaborating on Enoxaparin. J Invasive Cardiol 2000; 12 (Suppl E): E10-3.
22. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
23. Bertrand ME, Simoons ML, Fox KAA et al. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation: Recommendations of the task force of the European Society of Cardiology. Eur Heart J 2000: 21: 1406-32.
24. Cohen M, Demers C, Gurfinkel EP et al. for the Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
25. Antman EM, McCabe CH, Gurfinkel EP et al. for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999: 100: 1593-1601.
26. Rogers WJ, Canto JG, Lambrew CT et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: The National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36: 2056-63.
27. Rogers WJ, Canto JG, Barron HV, Boscarino JA, Shoultz DA, Every NR. Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Investigators in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2000; 35: 371-9.
28. Yusuf S. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. Am J Cardiol 1999; 84: 20M-25M.